Novartis stock heads into the open after a 0.4 percent dip

At the close on September 11, 2026, Novartis stock finished at CHF 112.04 on the SIX Swiss Exchange, down 0.36 percent, while the NYSE-listed shares slipped 0.19 percent. Recent coverage highlights the lingering impact of a late-week trial setback on sentiment.

Novartis stock closed at CHF 112.04 on the SIX Swiss Exchange on September 11, 2026, down 0.36 percent from the prior session. On the same date, the companys American depositary shares finished at USD 137.22 on the New York Stock Exchange, a decline of 0.19 percent. Per market data for the Swiss line, the CHF 112.04 close stood just above the sessions low of CHF 111.70 and below the high of CHF 112.44, leaving the shares modestly softer into todays session.

September 11, 2026 in numbers

Novartis AG (ISIN CH0012005267) saw its SIX Swiss Exchange line end the September 11, 2026 session at CHF 112.04, compared with a prior close of CHF 112.44, corresponding to a 0.36 percent decline. Intraday, the stock traded between a low of CHF 111.70 and a high of CHF 112.44, with the close near the lower half of that range, while a related Cboe Switzerland quotation showed the same CHF 112.04 last price for that date. A parallel listing in New York closed at USD 137.22 on September 11, 2026, down 0.26 in absolute terms or 0.19 percent from the previous day, as shown by NYSE data. According to a session wrap from Genetic Engineering & Biotechnology News, the shares were still digesting a double digit percentage drop earlier in the week after a phase III trial failure that erased more than a tenth of Novartis market value.

Outlook for today

Into todays session, investors are watching how trading develops after Erste Group Bank lifted its forecast for Novartis 2026 earnings per share, while maintaining a broadly cautious stance on the stock. As MarketBeat reported on September 14, 2026, the brokerage raised its 2026 EPS estimate and noted that the consensus rating on the stock remains at hold with an average target price of USD 153.00. In the background, sector news also continues to reference Novartis role as a development partner for Monte Rosa Therapeutics on the MRT-6160 program, after Monte Rosa announced on September 8, 2026 that the first patient had been dosed in a phase 2 trial, as highlighted by Yahoo Finance. These developments frame todays trading after the recent volatility around the failed phase III study.